8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Apr 12, 2021)

Filed April 12, 2021For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) disclosed in an 8-K filing dated April 12, 2021, that it received a subpoena on April 9, 2021, from the U.S. Department of Justice, U.S. Attorney's Office for the District of Massachusetts. The subpoena requests documents related to the marketing and promotion of Alnylam's drug ONPATTRO® (patisiran) within the United States. The company has stated its intention to cooperate fully with the government's investigation and is actively preparing its response. Alnylam has engaged experienced outside legal counsel to assist in managing this matter. While the nature and potential outcomes of such investigations are inherently uncertain, investors should monitor any further developments or disclosures regarding this subpoena as it could potentially impact the company's operations or reputation.

Key Highlights

  • 1Alnylam Pharmaceuticals received a subpoena from the U.S. Department of Justice.
  • 2The subpoena specifically targets documents related to the marketing and promotion of ONPATTRO® (patisiran).
  • 3The investigation pertains to activities within the United States.
  • 4The company is cooperating with the government and preparing a response.
  • 5Experienced outside legal counsel has been retained to assist in the matter.
  • 6The filing was made on April 12, 2021, with the subpoena received on April 9, 2021.

Frequently Asked Questions

Alnylam Pharmaceuticals received a subpoena from the U.S. Department of Justice, U.S. Attorney's Office for the District of Massachusetts, requesting documents concerning the marketing and promotion of its drug ONPATTRO® (patisiran) in the United States.

The company is cooperating with the government, is actively preparing its response to the subpoena, and has retained experienced outside legal counsel to assist with the matter.

ONPATTRO® (patisiran) is a drug developed by Alnylam Pharmaceuticals used for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).

The potential implications are currently uncertain as the investigation is in its early stages. Such government investigations can sometimes lead to fines, penalties, or changes in business practices, but it is too early to determine any specific outcomes for Alnylam.